MedPath

Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in Invasive Cardiology

Completed
Conditions
Renal Failure
Registration Number
NCT01612117
Lead Sponsor
University of Freiburg
Brief Summary

Diagnosis of acute kidney injury (AKI) relies on a late marker, namely serum creatinine (SCr). New biomarkers are considered for early and sensitive detection of CIN. In particular, uNGAL has been used for early detection of AKI in the emergency department, after cardiopulmonary bypass or following CM administration.

This study will be conducted to assess the possible value of urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as an early detector of contrast-induced nephropathy (CIN) in a large sized cohort of patients undergoing percutaneous coronary procedures (PCP) and whether or not uNGAL correlates with the volume of contrast medium (CM) used.

Detailed Description

Methods. We will enroll all consecutive patients undergoing PCP with iomeprolum during a 3-month period at our institution. CIN will be defined as a ≥25% increase in SCr from baseline when measured 2-4 days after PCP. uNGAL will be measured at its peak with the Abbott ARCHITECT assay.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
244
Inclusion Criteria
  • All except patients with exclusion criteria
Exclusion Criteria
  • dialysis-dependent chronic kidney disease
  • lack of written consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to assess the value of uNGAL measurement 4 to 6 hours after PCP as a possible early detector of CIN4-6 hours after PCP

cf title

Secondary Outcome Measures
NameTimeMethod
to study the relationship between the volume of contrast medium used for PCP and the uNGAL levels measured 4 to 6 hours thereafter4-6 hours after PCP

cf. title

Trial Locations

Locations (1)

Department of Cardiology

🇨🇭

Freiburg, Fribourg, Switzerland

© Copyright 2025. All Rights Reserved by MedPath